mycophenolic-acid and Fascioliasis

Fascioliasis is caused by the trematode liver fluke Fasciola hepatica. Humans are accidental hosts getting infected after ingesting contaminated plants or water. 90 million people in 75 nations are at risk of infection with F hepatica. Immunosuppressed patients are higher risk of acquiring infection and may present with atypical manifestations. Patients can present with hepatic involvement, biliary features or a combination of both. Confirmation of the diagnosis is by demonstration of live parasites or eggs in bile or feces, serology (immunoelectrophoresis, indirect immunofluorescence, indirect hemagglutination), ELISA, typical imaging findings or a combination of any of the above. The drug of choice for treatment is triclabendazole. Fascioliasis should always be considered as a possibility in post-LT patients with findings of hepatobiliary disorder from endemic areas. Unfamiliarity with this infection in non-endemic areas often eludes prompt diagnosis thereby increasing the morbidity. We report the first case of fascioliasis in a pediatric liver transplant recipient leading to graft loss and mortality.

Topics: Animals; Child; Cholangitis; Contrast Media; End Stage Liver Disease; Fasciola hepatica; Fascioliasis; Female; Graft Rejection; Humans; Immunosuppression Therapy; Immunosuppressive Agents; India; Liver Transplantation; Morocco; Mycophenolic Acid; Stem Cell Transplantation; Tacrolimus; Tomography, X-Ray Computed